C9orf72 Therapeutics Investment Landscape

Executive Summary

[C9orf72](/entities/c9orf72) hexanucleotide repeat expansion is the most common genetic cause of both amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), accounting for approximately 30-40% of familial ALS cases and 20-25% of familial FTD cases. This investment landscape summarizes therapeutic approaches targeting C9orf72 pathology, including antisense oligonucleotides (ASOs), small molecules, and gene therapy strategies. The field has advanced significantly with multiple clinical-stage programs and a robust preclinical pipeline targeting the three main pathological mechanisms: loss of function, RNA foci formation, and dipeptide repeat protein (DPR) toxicity. [@dejesushernandez2011]

Overview

This page summarizes R&D investment signals for C9orf72-targeted therapeutics in ALS and FTD. The C9orf72 gene encodes a DENN domain protein involved in endolysosomal trafficking and [autophagy](/entities/autophagy), and its expansion leads to both loss-of-function and gain-of-toxicity mechanisms. Therapeutic development focuses on: (1) reducing toxic RNA foci and DPRs; (2) restoring C9orf72 protein function; (3) addressing downstream effects including nucleocytoplasmic transport defects and mitochondrial dysfunction. [@renton2011]

Pipeline Summary

Clinical Trials

Executive Summary

[C9orf72](/entities/c9orf72) hexanucleotide repeat expansion is the most common genetic cause of both amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), accounting for approximately 30-40% of familial ALS cases and 20-25% of familial FTD cases. This investment landscape summarizes therapeutic approaches targeting C9orf72 pathology, including antisense oligonucleotides (ASOs), small molecules, and gene therapy strategies. The field has advanced significantly with multiple clinical-stage programs and a robust preclinical pipeline targeting the three main pathological mechanisms: loss of function, RNA foci formation, and dipeptide repeat protein (DPR) toxicity. [@dejesushernandez2011]

Overview

This page summarizes R&D investment signals for C9orf72-targeted therapeutics in ALS and FTD. The C9orf72 gene encodes a DENN domain protein involved in endolysosomal trafficking and [autophagy](/entities/autophagy), and its expansion leads to both loss-of-function and gain-of-toxicity mechanisms. Therapeutic development focuses on: (1) reducing toxic RNA foci and DPRs; (2) restoring C9orf72 protein function; (3) addressing downstream effects including nucleocytoplasmic transport defects and mitochondrial dysfunction. [@renton2011]

Pipeline Summary

Clinical Trials

| Program | Sponsor | Phase | Modality | Status | [@miller2020]
|---|---|---|---|---| [@liu2021]
| BIIB078 (ASO) | Biogen/Ionis | Phase 1/2 | Antisense Oligonucleotide | Completed |
| WVE-004 | Wave Life Sciences | Phase 1/2 | Antisense Oligonucleotide | Completed |
| ATNX-08045 | Accererant | Phase 1 | Antisense Oligonucleotide | Completed |

Preclinical Programs

| Program | Sponsor | Modality | Target |
|---|---|---|---|
| Multiple programs | Various | Small molecule | DPR aggregation inhibitors |
| Various | Academic consortia | Gene therapy | Viral vector delivery |
| Several programs | Biotech startups | RNA-targeting | RNA splicing modulators |

Therapeutic Approach Categories

1. Antisense Oligonucleotides (ASOs)

ASOs target the C9orf72 pre-mRNA to reduce the production of toxic dipeptide repeat proteins while preserving normal C9orf72 expression. Key programs include:

• BIIB078 (Biogen/Ionis): First-generation ASO targeting the expanded repeat. Completed Phase 1/2 trial but showed limited efficacy, leading to program discontinuation.
• WVE-004 (Wave Life Sciences): Stereopure ASO targeting C9orf72 transcript variants. Completed Phase 1/2 with modest results.
• Next-generation ASOs: Newer approaches focus on allele-selective targeting and improved CNS delivery.

2. Small Molecule Therapeutics

Small molecules offer oral bioavailability and potential for combination therapy:

• DPR aggregation inhibitors: Multiple programs targeting poly-GA, poly-GP, and poly-PR aggregation
• Autophagy enhancers: Targeting the lysosomal/autophagy pathway impaired in C9orf72 deficiency
• Nucleocytoplasmic transport modulators: Addressing the major downstream defect

3. Gene Therapy Approaches

• AAV-based gene silencing: Viral vector delivery of shRNA or miRNA constructs
• CRISPR-based editing: Emerging approaches for allele-specific editing
• Gene replacement: Restoring normal C9orf72 function

Market Opportunity

Disease Burden

• ALS: ~30,000-50,000 patients in the US, with C9orf72 accounting for ~10,000-15,000 cases
• FTD: ~50,000-60,000 patients in the US, with C9orf72 accounting for ~10,000-15,000 cases
• Total addressable population: ~20,000-30,000 patients in the US alone

Competitive Landscape

The C9orf72 therapeutic space is less crowded than other ALS targets (e.g., SOD1), offering potential first-mover advantages. Key competitors include:

• Biogen (via Ionis partnership)
• Wave Life Sciences
• Several emerging biotech companies
• Academic/clinical consortia

Research Gaps and Investment Opportunities

Unmet Needs

Priority Investment Areas

Key References

See Also

• [C9orf72 Gene](/genes/c9orf72)
• [C9orf72 Hexanucleotide Repeat Expansion Pathway](/mechanisms/c9orf72-hexanucleotide-repeat-expansion-als-ftd)
• [ALS Investment Landscape](/investment/als)
• [FTD Investment Landscape](/investment/ftd)
• [Antisense Oligonucleotide Therapy for C9orf72](/therapeutics/aso-c9orf72-als)

See Also

• [C9orf72 Gene](/entities/c9orf72)
• [ALS](/diseases/amyotrophic-lateral-sclerosis)
• [Frontotemporal Dementia](/diseases/frontotemporal-dementia)

External Links

• [ALS Association](https://www.als.org/)

References